Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia

Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia

US Patent 11873494 · Granted Jan 16, 2024

Estimated economic value: $1,500,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Inhibition of protein kinases to treat Friedreich ataxia2025
Inhibition of protein kinases to treat Friedreich ataxia2025
Therapeutic targets for facioscapulohumeral muscular dystrophy2024
Compositions and methods for modulating FMR1 expression2023
Compositions and methods for modulating FMR1 expression2023
Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome2023
SRPX for treatment of cancer2022
Compositions and methods for Xi chromosome reactivation2022
Method and system for access systems2021
Therapeutic targets for facioscapulohumeral muscular dystrophy2021
Genetic and pharmacological transcriptional upregulation of the repressed FXN ge2021
Genetic and pharmacological transcriptional upregulation of the repressed FXN ge2021